Company Description
Presidio is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties.
Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida.
Our office, industrial and retail properties are located primarily in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.
While geographical clustering of real estate enables us to reduce our operating costs through economies of scale by servicing several properties with less staff, it makes us susceptible to changing market conditions in these discrete geographic areas, including those that have developed as a result of COVID-19.
Presidio owns approximately 6.5% of the outstanding common stock of Conduit Pharmaceuticals Inc., a disease agnostic multi-asset clinical-stage disease-agnostic life science company providing an efficient model for compound development.
| Country | United States |
| IPO Date | Oct 7, 2020 |
| Industry | REIT - Diversified |
| Sector | Real Estate |
| Employees | 15 |
| CEO | Jack Kendrick Heilbron |
Contact Details
Address: 4995 Murphy Canyon Road, Suite 300 San Diego, California 92123 United States | |
| Phone | 760-471-8536 |
| Website | presidiopt.com |
Stock Details
| Ticker Symbol | SQFT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001080657 |
| CUSIP Number | 74102L303 |
| ISIN Number | US74102L3033 |
| Employer ID | 33-0841255 |
| SIC Code | 6798 |
Key Executives
| Name | Position |
|---|---|
| Jack Kendrick Heilbron | Chairman, President and Chief Executive Officer |
| Gary Morris Katz | Chief Investment Officer |
| Steve Hightower | President of Model Home Division and Director |
| Edwin H. Bentzen IV | Chief Financial Officer |
| Steven Foss | Director of Investor Relations |
| Sean Giffin | Director of Acquisitions and Asset Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 26, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 26, 2024 | 10-K/A | [Amend] Annual report |
| Apr 19, 2024 | PREC14A | Filing |
| Apr 17, 2024 | 10-K/A | [Amend] Annual report |
| Apr 16, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 16, 2024 | 10-K | Annual Report |
| Apr 11, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 11, 2024 | 8-K | Current Report |
| Apr 9, 2024 | 8-K | Current Report |
| Apr 3, 2024 | 8-K | Current Report |